Blincyto (blinatumomab)

pCPA File Number: 23056
Negotiation Status:
Active Negotiation
Indication(s):
Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
PX0367-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable